Review



human jurkat t cell leukemia cells  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    ATCC human jurkat t cell leukemia cells
    Human Jurkat T Cell Leukemia Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 573 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human jurkat t cell leukemia cells/product/ATCC
    Average 96 stars, based on 573 article reviews
    human jurkat t cell leukemia cells - by Bioz Stars, 2026-02
    96/100 stars

    Images



    Similar Products

    96
    ATCC human jurkat t cell leukemia cells
    Human Jurkat T Cell Leukemia Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human jurkat t cell leukemia cells/product/ATCC
    Average 96 stars, based on 1 article reviews
    human jurkat t cell leukemia cells - by Bioz Stars, 2026-02
    96/100 stars
      Buy from Supplier

    99
    ATCC human jurkat leukemia t cells
    Thromboxane agonists U46619 (A-D), TXA2 (E-G), and TXB2 (H-J) increase NEU-1 sialidase activity in <t>Jurkat</t> T-cells dose-dependently, while OP, MMP9i, and BIM23 inhibitors of signaling paradigm (A) reverse thromboxane agonists NEU-1 activity. Jurkat cells were treated with indicated agonist doses and further treated in combination with the inhibitors for one minute. 4-MUNANA substrate was added to live cells to measure sialidase activity (emission 450 nm, excitation 365 nm). The mean ± SEM (biological replicates: 5, technical replicates: 50) fluorescence density of sialidase activity demonstrates a highly significant (p < 0.0001) downregulation of sialidase activity with all three inhibitors. A normal QQ plot depicts the normality of each of the datasets, modeled by a normal distribution. Abbreviations: TGFβ-1: transforming growth factor beta-1; IL-6: in-terleukin-6; HGF: hepatocyte growth factor; OP: oseltamivir phosphate; MMP9i: MMP9 inhibitor; BIM23: BIM-23127. **** p < 0.0001.
    Human Jurkat Leukemia T Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human jurkat leukemia t cells/product/ATCC
    Average 99 stars, based on 1 article reviews
    human jurkat leukemia t cells - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    96
    ATCC human t cell acute lymphoblastic leukemia cell jurkat
    Thromboxane agonists U46619 (A-D), TXA2 (E-G), and TXB2 (H-J) increase NEU-1 sialidase activity in <t>Jurkat</t> T-cells dose-dependently, while OP, MMP9i, and BIM23 inhibitors of signaling paradigm (A) reverse thromboxane agonists NEU-1 activity. Jurkat cells were treated with indicated agonist doses and further treated in combination with the inhibitors for one minute. 4-MUNANA substrate was added to live cells to measure sialidase activity (emission 450 nm, excitation 365 nm). The mean ± SEM (biological replicates: 5, technical replicates: 50) fluorescence density of sialidase activity demonstrates a highly significant (p < 0.0001) downregulation of sialidase activity with all three inhibitors. A normal QQ plot depicts the normality of each of the datasets, modeled by a normal distribution. Abbreviations: TGFβ-1: transforming growth factor beta-1; IL-6: in-terleukin-6; HGF: hepatocyte growth factor; OP: oseltamivir phosphate; MMP9i: MMP9 inhibitor; BIM23: BIM-23127. **** p < 0.0001.
    Human T Cell Acute Lymphoblastic Leukemia Cell Jurkat, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human t cell acute lymphoblastic leukemia cell jurkat/product/ATCC
    Average 96 stars, based on 1 article reviews
    human t cell acute lymphoblastic leukemia cell jurkat - by Bioz Stars, 2026-02
    96/100 stars
      Buy from Supplier

    99
    ATCC human acute t cell leukemia line jurkat
    Thromboxane agonists U46619 (A-D), TXA2 (E-G), and TXB2 (H-J) increase NEU-1 sialidase activity in <t>Jurkat</t> T-cells dose-dependently, while OP, MMP9i, and BIM23 inhibitors of signaling paradigm (A) reverse thromboxane agonists NEU-1 activity. Jurkat cells were treated with indicated agonist doses and further treated in combination with the inhibitors for one minute. 4-MUNANA substrate was added to live cells to measure sialidase activity (emission 450 nm, excitation 365 nm). The mean ± SEM (biological replicates: 5, technical replicates: 50) fluorescence density of sialidase activity demonstrates a highly significant (p < 0.0001) downregulation of sialidase activity with all three inhibitors. A normal QQ plot depicts the normality of each of the datasets, modeled by a normal distribution. Abbreviations: TGFβ-1: transforming growth factor beta-1; IL-6: in-terleukin-6; HGF: hepatocyte growth factor; OP: oseltamivir phosphate; MMP9i: MMP9 inhibitor; BIM23: BIM-23127. **** p < 0.0001.
    Human Acute T Cell Leukemia Line Jurkat, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human acute t cell leukemia line jurkat/product/ATCC
    Average 99 stars, based on 1 article reviews
    human acute t cell leukemia line jurkat - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    99
    ATCC human t cell leukemia cell line jurkat
    Thromboxane agonists U46619 (A-D), TXA2 (E-G), and TXB2 (H-J) increase NEU-1 sialidase activity in <t>Jurkat</t> T-cells dose-dependently, while OP, MMP9i, and BIM23 inhibitors of signaling paradigm (A) reverse thromboxane agonists NEU-1 activity. Jurkat cells were treated with indicated agonist doses and further treated in combination with the inhibitors for one minute. 4-MUNANA substrate was added to live cells to measure sialidase activity (emission 450 nm, excitation 365 nm). The mean ± SEM (biological replicates: 5, technical replicates: 50) fluorescence density of sialidase activity demonstrates a highly significant (p < 0.0001) downregulation of sialidase activity with all three inhibitors. A normal QQ plot depicts the normality of each of the datasets, modeled by a normal distribution. Abbreviations: TGFβ-1: transforming growth factor beta-1; IL-6: in-terleukin-6; HGF: hepatocyte growth factor; OP: oseltamivir phosphate; MMP9i: MMP9 inhibitor; BIM23: BIM-23127. **** p < 0.0001.
    Human T Cell Leukemia Cell Line Jurkat, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human t cell leukemia cell line jurkat/product/ATCC
    Average 99 stars, based on 1 article reviews
    human t cell leukemia cell line jurkat - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    94
    ATCC jurkat t cells human acute t cell leukemia
    Thromboxane agonists U46619 (A-D), TXA2 (E-G), and TXB2 (H-J) increase NEU-1 sialidase activity in <t>Jurkat</t> T-cells dose-dependently, while OP, MMP9i, and BIM23 inhibitors of signaling paradigm (A) reverse thromboxane agonists NEU-1 activity. Jurkat cells were treated with indicated agonist doses and further treated in combination with the inhibitors for one minute. 4-MUNANA substrate was added to live cells to measure sialidase activity (emission 450 nm, excitation 365 nm). The mean ± SEM (biological replicates: 5, technical replicates: 50) fluorescence density of sialidase activity demonstrates a highly significant (p < 0.0001) downregulation of sialidase activity with all three inhibitors. A normal QQ plot depicts the normality of each of the datasets, modeled by a normal distribution. Abbreviations: TGFβ-1: transforming growth factor beta-1; IL-6: in-terleukin-6; HGF: hepatocyte growth factor; OP: oseltamivir phosphate; MMP9i: MMP9 inhibitor; BIM23: BIM-23127. **** p < 0.0001.
    Jurkat T Cells Human Acute T Cell Leukemia, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/jurkat t cells human acute t cell leukemia/product/ATCC
    Average 94 stars, based on 1 article reviews
    jurkat t cells human acute t cell leukemia - by Bioz Stars, 2026-02
    94/100 stars
      Buy from Supplier

    99
    ATCC human t cell leukemia cell line
    Thromboxane agonists U46619 (A-D), TXA2 (E-G), and TXB2 (H-J) increase NEU-1 sialidase activity in <t>Jurkat</t> T-cells dose-dependently, while OP, MMP9i, and BIM23 inhibitors of signaling paradigm (A) reverse thromboxane agonists NEU-1 activity. Jurkat cells were treated with indicated agonist doses and further treated in combination with the inhibitors for one minute. 4-MUNANA substrate was added to live cells to measure sialidase activity (emission 450 nm, excitation 365 nm). The mean ± SEM (biological replicates: 5, technical replicates: 50) fluorescence density of sialidase activity demonstrates a highly significant (p < 0.0001) downregulation of sialidase activity with all three inhibitors. A normal QQ plot depicts the normality of each of the datasets, modeled by a normal distribution. Abbreviations: TGFβ-1: transforming growth factor beta-1; IL-6: in-terleukin-6; HGF: hepatocyte growth factor; OP: oseltamivir phosphate; MMP9i: MMP9 inhibitor; BIM23: BIM-23127. **** p < 0.0001.
    Human T Cell Leukemia Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human t cell leukemia cell line/product/ATCC
    Average 99 stars, based on 1 article reviews
    human t cell leukemia cell line - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    99
    ATCC human t cell leukemia line jurkat
    Thromboxane agonists U46619 (A-D), TXA2 (E-G), and TXB2 (H-J) increase NEU-1 sialidase activity in <t>Jurkat</t> T-cells dose-dependently, while OP, MMP9i, and BIM23 inhibitors of signaling paradigm (A) reverse thromboxane agonists NEU-1 activity. Jurkat cells were treated with indicated agonist doses and further treated in combination with the inhibitors for one minute. 4-MUNANA substrate was added to live cells to measure sialidase activity (emission 450 nm, excitation 365 nm). The mean ± SEM (biological replicates: 5, technical replicates: 50) fluorescence density of sialidase activity demonstrates a highly significant (p < 0.0001) downregulation of sialidase activity with all three inhibitors. A normal QQ plot depicts the normality of each of the datasets, modeled by a normal distribution. Abbreviations: TGFβ-1: transforming growth factor beta-1; IL-6: in-terleukin-6; HGF: hepatocyte growth factor; OP: oseltamivir phosphate; MMP9i: MMP9 inhibitor; BIM23: BIM-23127. **** p < 0.0001.
    Human T Cell Leukemia Line Jurkat, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human t cell leukemia line jurkat/product/ATCC
    Average 99 stars, based on 1 article reviews
    human t cell leukemia line jurkat - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    Image Search Results


    Thromboxane agonists U46619 (A-D), TXA2 (E-G), and TXB2 (H-J) increase NEU-1 sialidase activity in Jurkat T-cells dose-dependently, while OP, MMP9i, and BIM23 inhibitors of signaling paradigm (A) reverse thromboxane agonists NEU-1 activity. Jurkat cells were treated with indicated agonist doses and further treated in combination with the inhibitors for one minute. 4-MUNANA substrate was added to live cells to measure sialidase activity (emission 450 nm, excitation 365 nm). The mean ± SEM (biological replicates: 5, technical replicates: 50) fluorescence density of sialidase activity demonstrates a highly significant (p < 0.0001) downregulation of sialidase activity with all three inhibitors. A normal QQ plot depicts the normality of each of the datasets, modeled by a normal distribution. Abbreviations: TGFβ-1: transforming growth factor beta-1; IL-6: in-terleukin-6; HGF: hepatocyte growth factor; OP: oseltamivir phosphate; MMP9i: MMP9 inhibitor; BIM23: BIM-23127. **** p < 0.0001.

    Journal: bioRxiv

    Article Title: Mammalian Neuraminidase-1 is a Critical Regulator of Platelet-derived Thromboxane A2 (TXA2) T-cell Immunosuppression to Promote Tumor Progression and Metastasis

    doi: 10.64898/2025.12.01.691391

    Figure Lengend Snippet: Thromboxane agonists U46619 (A-D), TXA2 (E-G), and TXB2 (H-J) increase NEU-1 sialidase activity in Jurkat T-cells dose-dependently, while OP, MMP9i, and BIM23 inhibitors of signaling paradigm (A) reverse thromboxane agonists NEU-1 activity. Jurkat cells were treated with indicated agonist doses and further treated in combination with the inhibitors for one minute. 4-MUNANA substrate was added to live cells to measure sialidase activity (emission 450 nm, excitation 365 nm). The mean ± SEM (biological replicates: 5, technical replicates: 50) fluorescence density of sialidase activity demonstrates a highly significant (p < 0.0001) downregulation of sialidase activity with all three inhibitors. A normal QQ plot depicts the normality of each of the datasets, modeled by a normal distribution. Abbreviations: TGFβ-1: transforming growth factor beta-1; IL-6: in-terleukin-6; HGF: hepatocyte growth factor; OP: oseltamivir phosphate; MMP9i: MMP9 inhibitor; BIM23: BIM-23127. **** p < 0.0001.

    Article Snippet: Human Jurkat leukemia T cells (Clone E6-1, TIB-152 TM) obtained from the American Type Culture Collection, Manassas, VA 20110-2209, USA, are an immortalized human T-lymphocyte cell line derived from a patient with T-cell acute lymphoblastic leukemia (T-ALL).

    Techniques: Activity Assay, Fluorescence

    (A) Thromboxane TXA2 GPCR colocalizes with NEU-1 in Jurkat T-cells. (B) Cells were fixed, permeabilized, blocked, and immunostained with the specific antibodies. Cells were treated with Alexa Fluor™ 594-conjugated antibody for the TXA2 GPCR and Alexa Fluor™ 488-conjugated NEU-1 monoclonal antibody. (A) Merging of fluorescent images acquired from Zeiss M2 epi-fluorescent microscope (20× objective magnification) shows areas of colocalization through yellow fluorescence. Pearson correlation coefficient (R-value) measured a moderate positive correlation (0.4 < r < 0.5) between the TXA2 GPCR and NEU-1 (biological replicates: 4, technical replicates).

    Journal: bioRxiv

    Article Title: Mammalian Neuraminidase-1 is a Critical Regulator of Platelet-derived Thromboxane A2 (TXA2) T-cell Immunosuppression to Promote Tumor Progression and Metastasis

    doi: 10.64898/2025.12.01.691391

    Figure Lengend Snippet: (A) Thromboxane TXA2 GPCR colocalizes with NEU-1 in Jurkat T-cells. (B) Cells were fixed, permeabilized, blocked, and immunostained with the specific antibodies. Cells were treated with Alexa Fluor™ 594-conjugated antibody for the TXA2 GPCR and Alexa Fluor™ 488-conjugated NEU-1 monoclonal antibody. (A) Merging of fluorescent images acquired from Zeiss M2 epi-fluorescent microscope (20× objective magnification) shows areas of colocalization through yellow fluorescence. Pearson correlation coefficient (R-value) measured a moderate positive correlation (0.4 < r < 0.5) between the TXA2 GPCR and NEU-1 (biological replicates: 4, technical replicates).

    Article Snippet: Human Jurkat leukemia T cells (Clone E6-1, TIB-152 TM) obtained from the American Type Culture Collection, Manassas, VA 20110-2209, USA, are an immortalized human T-lymphocyte cell line derived from a patient with T-cell acute lymphoblastic leukemia (T-ALL).

    Techniques: Microscopy, Fluorescence

    Analyses of Jurkat T-cells for ARCGH1 expression following 24-hour exposure to TXA2 in a combination of ASA, celecoxib and OP cocktail using immunocytochemistry. (A) Jurkat T-cells were plated at 150,000 cell/mL and left untreated, treated with TXA2 (10 µM) in combination with OP (300 µg/mL), ASP (6.4 mM) or celecoxib (0.2 mM) for 24 hours. Cells were immunostained for ARCGH1 expression using rabbit anti-ARHGEF1 and secondary goat anti-rabbit -Alexa 594. The results are depicted as a scatter plot of data visualization using dots to represent the indicated ARCGH1 expression values obtained from 2 independent experiments of multiple images (n = 4–10). The mean density staining corrected for background (Bkg) ± S.E.M. for indicated ARCGH1 expression values is indicated for each group. The density staining values of each group were compared to the untreated control as well as TXA2 in combination with inhibitor cocktail by ANOVA using the uncorrected Fisher’s LSD multiple comparisons test with 95% confidence with indicated asterisks for statistical significance. (B) Immunocytochemistry of untreated and TXA2 (10 μM) treated Jurkat cells for 24 hrs in combination with ASP, celecoxib and OP. Data are presented as the percentage of cells expressing ARCGH1corrected for background autofluorescence. ns, not significant, * p ≤ 0.01, ** p ≤ 0.001, *** p ≤ 0.0001. Abbreviations: ASP, aspirin (acetylsalicylic acid); celec, celecoxib; OP, oseltamivir phosphate.

    Journal: bioRxiv

    Article Title: Mammalian Neuraminidase-1 is a Critical Regulator of Platelet-derived Thromboxane A2 (TXA2) T-cell Immunosuppression to Promote Tumor Progression and Metastasis

    doi: 10.64898/2025.12.01.691391

    Figure Lengend Snippet: Analyses of Jurkat T-cells for ARCGH1 expression following 24-hour exposure to TXA2 in a combination of ASA, celecoxib and OP cocktail using immunocytochemistry. (A) Jurkat T-cells were plated at 150,000 cell/mL and left untreated, treated with TXA2 (10 µM) in combination with OP (300 µg/mL), ASP (6.4 mM) or celecoxib (0.2 mM) for 24 hours. Cells were immunostained for ARCGH1 expression using rabbit anti-ARHGEF1 and secondary goat anti-rabbit -Alexa 594. The results are depicted as a scatter plot of data visualization using dots to represent the indicated ARCGH1 expression values obtained from 2 independent experiments of multiple images (n = 4–10). The mean density staining corrected for background (Bkg) ± S.E.M. for indicated ARCGH1 expression values is indicated for each group. The density staining values of each group were compared to the untreated control as well as TXA2 in combination with inhibitor cocktail by ANOVA using the uncorrected Fisher’s LSD multiple comparisons test with 95% confidence with indicated asterisks for statistical significance. (B) Immunocytochemistry of untreated and TXA2 (10 μM) treated Jurkat cells for 24 hrs in combination with ASP, celecoxib and OP. Data are presented as the percentage of cells expressing ARCGH1corrected for background autofluorescence. ns, not significant, * p ≤ 0.01, ** p ≤ 0.001, *** p ≤ 0.0001. Abbreviations: ASP, aspirin (acetylsalicylic acid); celec, celecoxib; OP, oseltamivir phosphate.

    Article Snippet: Human Jurkat leukemia T cells (Clone E6-1, TIB-152 TM) obtained from the American Type Culture Collection, Manassas, VA 20110-2209, USA, are an immortalized human T-lymphocyte cell line derived from a patient with T-cell acute lymphoblastic leukemia (T-ALL).

    Techniques: Expressing, Immunocytochemistry, Staining, Control